Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.creator | Santos, Fernanda Nunes | - |
Autor(es): dc.creator | Borja-Cabrera, Gulnara Patricia | - |
Autor(es): dc.creator | Myashiro, L. M. | - |
Autor(es): dc.creator | Grechi, Juliana | - |
Autor(es): dc.creator | Reis, Alexandre Barbosa | - |
Autor(es): dc.creator | Moreira, Márcio Antônio Batistela | - |
Autor(es): dc.creator | Martins Filho, Olindo Assis | - |
Autor(es): dc.creator | Luvizotto, Maria Cecília Rui | - |
Autor(es): dc.creator | Menz, Ingrid | - |
Autor(es): dc.creator | Pessôa, L. M. | - |
Autor(es): dc.creator | Gonçalves, Pablo Rodrigues | - |
Autor(es): dc.creator | Palatnik, Marcos | - |
Autor(es): dc.creator | Souza, Clarisa Beatriz Palatnik de | - |
Data de aceite: dc.date.accessioned | 2019-11-06T13:24:14Z | - |
Data de disponibilização: dc.date.available | 2019-11-06T13:24:14Z | - |
Data de envio: dc.date.issued | 2012-07-10 | - |
Data de envio: dc.date.issued | 2012-07-10 | - |
Data de envio: dc.date.issued | 2007 | - |
Fonte completa do material: dc.identifier | http://hdl.handle.net/123456789/1042 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/554657 | - |
Descrição: dc.description | In order to assess the immunotherapeutic potential on canine visceral leishmaniasis of the Leishmune ® vaccine, formulated with an increased adjuvant concentration (1 mg of saponin rather than 0.5 mg), 24 mongrel dogs were infected with Leishmania (L.) chagasi . The enriched-Leishmune ® vaccine was injected on month 6, 7 and 8 after infection, when animals were seropositive and symptomatic. The control group were injected with a saline solution. Leishmune ® -treated dogs showed significantly higher levels of anti-FML IgG antibodies (ANOVA; p < 0.0001), a higher and stable IgG2 and a decreasing IgG1 response, pointing to a TH1 T cell mediated response. The vaccine had the following effects: it led to more positive delayed type hypersensitivity reactions against Leishmania lysate in vaccinated dogs (75%) than in controls (50%), to a decreased average of CD4+ Leishmania -specific lymphocytes in saline controls (32.13%) that fell outside the 95% confidence interval of the vaccinees (41.62%, CI95% 43.93–49.80) and an increased average of the clinical scores from the saline controls (17.83) that falls outside the 95% confidence interval for the Leishmune ® immunotherapy-treated dogs (15.75, CI95% 13.97–17.53). All dogs that received the vaccine were clustered, and showed lower clinical scores and normal CD4+ counts, whereas 42% of the untreated dogs showed very diminished CD4+ and higher clinical score. The increase in clinical signs of the saline treated group was correlated with an increase in anti-FML antibodies (p < 0.0001), the parasitological evidence ( p = 0.038) and a decrease inLeishmania -specific CD4+ lymphocyte proportions (p = 0.035). These results confirm the immunotherapeutic potential of the enriched-Leishmune ® vaccine. The vaccine reduced the clinical symptoms and evidence of parasite, modulating the outcome of the infection and the dog’s potential infectiosity to phlebotomines. The enriched-Leishmune ® vaccine was subjected to a safety analysis and found to be well tolerated and safe | - |
Idioma: dc.language | en | - |
Direitos: dc.rights | O Periódico Vaccine concede permissão para depósito deste artigo no Repositório Institucional da UFOP. Número da licença: 3291410128861. | - |
Palavras-chave: dc.subject | FML-vaccine | - |
Palavras-chave: dc.subject | Immunotherapy | - |
Palavras-chave: dc.subject | Leishmune | - |
Palavras-chave: dc.subject | vaccine | - |
Palavras-chave: dc.subject | Canine visceral leishmaniasis | - |
Título: dc.title | Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. | - |
Aparece nas coleções: | Repositório Institucional - UFOP |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: